Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications

Thoren, Fredrik B. ; Anderson, Harald LU and Strannegard, Orjan (2013) In Cancer Immunology and Immunotherapy 62(10). p.1547-1551
Abstract
Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical... (More)
Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Immunotherapy, Survival analysis, Kaplan-Meier, Treatment outcome, Late, divergence, Statistical models
in
Cancer Immunology and Immunotherapy
volume
62
issue
10
pages
1547 - 1551
publisher
Springer
external identifiers
  • wos:000325008800001
  • scopus:84885836084
  • pmid:23979447
ISSN
1432-0851
DOI
10.1007/s00262-013-1458-y
language
English
LU publication?
yes
id
f5467b91-27bf-4cd3-9645-55392a4baace (old id 4172494)
date added to LUP
2016-04-01 13:53:19
date last changed
2022-01-27 21:38:19
@article{f5467b91-27bf-4cd3-9645-55392a4baace,
  abstract     = {{Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point.}},
  author       = {{Thoren, Fredrik B. and Anderson, Harald and Strannegard, Orjan}},
  issn         = {{1432-0851}},
  keywords     = {{Immunotherapy; Survival analysis; Kaplan-Meier; Treatment outcome; Late; divergence; Statistical models}},
  language     = {{eng}},
  number       = {{10}},
  pages        = {{1547--1551}},
  publisher    = {{Springer}},
  series       = {{Cancer Immunology and Immunotherapy}},
  title        = {{Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications}},
  url          = {{https://lup.lub.lu.se/search/files/3650645/4436550.pdf}},
  doi          = {{10.1007/s00262-013-1458-y}},
  volume       = {{62}},
  year         = {{2013}},
}